Does Rallies show Form 4 insider transactions for MNKD?

Yes. Rallies tracks MNKD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MNKD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MNKD. It does not provide personalized investment advice.

MNKD (Mannkind Corporation) Stock Analysis - Insider Trades

Mannkind Corporation (MNKD) is a publicly traded Healthcare sector company. As of May 21, 2026, MNKD trades at $3.29 with a market cap of $923.76M and a P/E ratio of -45.64. MNKD moved +9.46% today. Year to date, MNKD is -42.17%; over the trailing twelve months it is -25.37%. Its 52-week range spans $2.23 to $7.63. Analyst consensus is strong buy with an average price target of $7.54. Rallies surfaces MNKD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MNKD stock inside the company?

Recent MNKD insider activity includes Binder Steven B. sold 16.94K, Thomson David sold 3.03K, Castagna Michael bought 100.00K, Tross Stuart A sold 47.01K, and Castagna Michael sold 65.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MNKD Key Metrics

Key financial metrics for MNKD
Metric	Value
Price	$3.29
Market Cap	$923.76M
P/E Ratio	-45.64
EPS	$-0.07
Dividend Yield	0.00%
52-Week High	$7.63
52-Week Low	$2.23
Volume	6.98K
Avg Volume	0
Revenue (TTM)	$360.78M
Net Income	$-23.91M
Gross Margin	91.53%

Recent MNKD Insider Trades

Binder Steven B. sold 16.94K (~$55.73K) on May 12, 2026.
Thomson David sold 3.03K (~$9.98K) on May 12, 2026.
Castagna Michael bought 100.00K (~$259.00K) on Mar 10, 2026.
Tross Stuart A sold 47.01K (~$297.55K) on Jan 8, 2026.
Castagna Michael sold 65.80K (~$395.48K) on Dec 17, 2025.

Latest MNKD News

MannKind Q1 Revenues Rise 15% to $90.2M; PDUFA Dates for Afrezza Pediatric and Furoscix ReadyFlow — May 6, 2026
MannKind Secures $5M Advance and Potential $35M Milestones for Ralinepag DPI Program — May 6, 2026
MannKind to Present Inhaled Afrezza Pediatric Data, FDA PDUFA Set for May 29, 2026 — Mar 9, 2026
MannKind Achieves 46% Q4 Revenue Growth to $112M and Settles $36.3M Notes — Mar 6, 2026
MannKind Reports 46% Revenue Surge, Targets $450M+ with Afrezza Growth — Mar 1, 2026

MNKD Analyst Consensus

8 analysts cover MNKD: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.54.

Common questions about MNKD

Who is trading MNKD stock inside the company?: Recent MNKD insider activity includes Binder Steven B. sold 16.94K, Thomson David sold 3.03K, Castagna Michael bought 100.00K, Tross Stuart A sold 47.01K, and Castagna Michael sold 65.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MNKD?: Yes. Rallies tracks MNKD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MNKD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MNKD. It does not provide personalized investment advice.